DGIdb - BRCA1 Gene Record

BRCA1 672 Druggable GenomeClinically ActionableDrug Resistance

Alternate Names:

672
BRCA1, DNA REPAIR ASSOCIATED
BRCA1
BRCAI
BRCC1
BROVCA1
FANCS
IRIS
PNCA4
PPP1R53
PSCP
RNF53
113705
1100
ENSG00000012048
OTTHUMG00000157426
PA25411
P38398
6

Gene Info:

Gene Biotype	PROTEIN_CODING

(12 More Sources)

Gene Categories: Category Details

DRUG RESISTANCE
DRUGGABLE GENOME
CLINICALLY ACTIONABLE
ENZYME

Publications:

Tassone et al., 2003, BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells., Br. J. Cancer
Kummar et al., 2015, Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer., Clin. Cancer Res.
Rodler et al., 2016, Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer., Clin. Cancer Res.
LoRusso et al., 2016, Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors., Clin. Cancer Res.
Karginova et al., 2015, Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer., Mol. Cancer Ther.
O'Reilly EM et al., 2018, Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma., Cancer
Golan T et al., 2014, Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers., Br J Cancer
Mo et al., 2016, mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer., Clin. Cancer Res.
Drost et al., 2011, BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance., Cancer Cell
Drost et al., 2016, BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1., J. Clin. Invest.
Hunter et al., 2014, Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer., Mol. Cancer Ther.
Kaufman et al., 2015, Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation., J. Clin. Oncol.
Tutt et al., 2010, Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial., Lancet
2017 Aug 9, Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation., N Engl J Med
Gelmon et al., 2011, Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study., Lancet Oncol.
Liu et al., 2014, Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study., Lancet Oncol.
Fong et al., 2009, Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers., N. Engl. J. Med.
Robson et al., 2017, Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation., N. Engl. J. Med.
Goff, 2013, Advanced ovarian cancer: what should be the standard of care?, J Gynecol Oncol
Golan T et al., 2019, Maintenance Olaparib for Germline <i>BRCA</i>-Mutated Metastatic Pancreatic Cancer., N Engl J Med
Marshall CH et al., 2019, Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations., Eur Urol
Moore K et al., 2018, Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer., N Engl J Med
Ledermann J et al., 2014, Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial., Lancet Oncol
Caulfield SE et al., 2019, Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a <i>BRCA</i>1/2 Mutation., J Adv Pract Oncol
Wang et al., 2016, RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance., J. Clin. Invest.
Drew et al., 2016, Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer., Br. J. Cancer
Du et al., 2016, Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors., Nat. Med.
Kondrashova O et al., 2017 Sep, Secondary Somatic Mutations Restoring <i>RAD51C</i> and <i>RAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma., Cancer Discov
Swisher et al., 2017, Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial., Lancet Oncol.
Quinn et al., 2003, BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis., Cancer Res.
Narod SA et al., 2000, Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group., Lancet
Pierce LJ et al., 2006, Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer., J Clin Oncol
Gronwald J et al., 2006, Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update., Int J Cancer
Metcalfe K et al., 2004, Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers., J Clin Oncol
Jones et al., 2005, Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer., Oncogene
Leijen et al., 2016, Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months., J. Clin. Oncol.
Sandhu et al., 2013, The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial., Lancet Oncol.
Mirza et al., 2016, Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer., N. Engl. J. Med.
Nolan et al., 2016, RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers., Nat. Med.
Fedier et al., 2003, The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells., Int. J. Oncol.
Wiltshire et al., 2007, BRCA1 contributes to cell cycle arrest and chemoresistance in response to the anticancer agent irofulven., Mol. Pharmacol.
Xing et al., 2006, A mouse model for the molecular characterization of brca1-associated ovarian carcinoma., Cancer Res.
Isakoff et al., 2015, TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer., J. Clin. Oncol.
Vollebergh et al., 2011, An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients., Ann. Oncol.
Xu et al., 2017, CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours., Nat Commun
McGonigle et al., 2015, E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling., Oncotarget
de Bono et al., 2017, Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers., Cancer Discov
Shen et al., 2013, BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency., Clin. Cancer Res.
Srinivas et al., 2004, Antisense blocking of BRCA1 enhances sensitivity to plumbagin but not tamoxifen in BG-1 ovarian cancer cells., Mol. Carcinog.

GAMMA-FAGARINE BRCA1

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
7-HYDROXYFLAVONE BRCA1

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
2-PHENYLQUINOLINE BRCA1

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL1709259 BRCA1

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
GLABRIDIN BRCA1

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL12658 BRCA1

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL1404865 BRCA1

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL273891 BRCA1

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DENOSUMAB BRCA1

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Emerging

Approval Status Clinical Study

Response Type not applicable

PMIDs:
27322743

Sources:
JAX-CKB
CHEMBL1481721 BRCA1

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL1333798 BRCA1

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
WISTIN BRCA1

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL1320798 BRCA1

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL446567 BRCA1

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
VELIPARIB BRCA1

Interaction Score: 0.53

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Veliparib;Cisplatin

Drug family PARP inhibitor;Chemotherapy

Alteration BRCA1:.

PMIDs:
25589624 26801247 26842236 25824335 29338080

Sources:
ClearityFoundationBiomarkers JAX-CKB CGI CIViC
OLAPARIB BRCA1

Interaction Score: 0.45

Interaction Types & Directionality:

n/a

Interaction Info:

Alteration BRCA1:.

Drug family PARP inhibitor

Indication/Tumor Type breast cancer

PMIDs:
26546619 22172724 27454287 25193512 25366685 20609467 28792849 21862407 25218906 19553641 28578601 23346317 31157963 30797618 30345884 24882434 31538027

Sources:
ClearityFoundationBiomarkers JAX-CKB CGI CIViC PharmGKB OncoKB
QUARFLOXIN BRCA1

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28211448

Sources:
CIViC
NIRAPARIB BRCA1

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type ovarian cancer

Response Type sensitive

Approval Status FDA approved

PMIDs:
23810788 27717299

Sources:
ClearityFoundationBiomarkers JAX-CKB PharmGKB OncoKB
TALAZOPARIB BRCA1

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Preclinical

PMIDs:
26546619 28242752 23881923

Sources:
JAX-CKB CIViC PharmGKB OncoKB
CHEMBL600315 BRCA1

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL1078244 BRCA1

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
2X-121 BRCA1

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type triple-receptor negative breast cancer

Response Type predicted – sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
26513298

Sources:
ClearityFoundationBiomarkers JAX-CKB
CHEMBL589207 BRCA1

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SEMUSTINE BRCA1

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL153505 BRCA1

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
IROFULVEN BRCA1

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17229870

Sources:
NCI
CHEMBL1308677 BRCA1

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
THUNBERGINOL E BRCA1

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL66279 BRCA1

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL593254 BRCA1

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CALYCOSIN BRCA1

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHRYSIN DIMETHYL ETHER BRCA1

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL316796 BRCA1

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ILEPCIMIDE BRCA1

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TIAPROFENIC ACID BRCA1

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PAMIPARIB BRCA1

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type breast cancer

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
None found

Sources:
JAX-CKB
CHEMBL588525 BRCA1

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
RUCAPARIB BRCA1

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type ovarian carcinoma

Response Type sensitive

Approval Status Clinical Study

PMIDs:
27454289 27002934 26779812 28588062 27908594

Sources:
ClearityFoundationBiomarkers JAX-CKB CGI CIViC PharmGKB OncoKB
CHEMBL1214407 BRCA1

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL588683 BRCA1

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
RIBOFLAVIN BRCA1

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DIMETHYL YELLOW BRCA1

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL1405979 BRCA1

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DAIDZIN BRCA1

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
HARMALOL BRCA1

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
VITAMIN B2 BRCA1

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
6-HYDROXYFLAVONE BRCA1

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL515763 BRCA1

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL1998001 BRCA1

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL587620 BRCA1

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL452954 BRCA1

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
7-HYDROXY ISOFLAVONE BRCA1

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
NILE RED BRCA1

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ONONIN BRCA1

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL546649 BRCA1

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL1420181 BRCA1

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL1574420 BRCA1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TANSHINONE IIA SULFONATE BRCA1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
THIABENDAZOLE BRCA1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHLORAMBUCIL BRCA1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
25193512

Sources:
JAX-CKB
CHEMBL546865 BRCA1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL581910 BRCA1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PHENAMIL METHANESULFONATE BRCA1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL581929 BRCA1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
VINORELBINE BRCA1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Phase I

Response Type sensitive

PMIDs:
26801247 14559807

Sources:
JAX-CKB NCI
PIFEXOLE BRCA1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL114544 BRCA1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL484663 BRCA1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
BERZOSERTIB BRCA1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type predicted – sensitive

Indication/Tumor Type triple-receptor negative breast cancer

combination therapy Cisplatin + VX-970

PMIDs:
None found

Sources:
JAX-CKB
TAMOXIFEN BRCA1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11130383 16636335 16331614 15197194 15750629

Sources:
NCI PharmGKB
CHEMBL323356 BRCA1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
BLEOMYCIN BRCA1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14559807

Sources:
NCI
CARBOPLATIN BRCA1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Carboplatin + VX-970

Indication/Tumor Type ovarian cancer

Response Type sensitive

PMIDs:
25847936 27998224 25824335 21135055

Sources:
ClearityFoundationBiomarkers JAX-CKB CIViC
OXALIPLATIN BRCA1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25072261

Sources:
ClearityFoundationBiomarkers CIViC
CISPLATIN BRCA1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Veliparib;Cisplatin

Drug family PARP inhibitor;Chemotherapy

Alteration BRCA1:.

PMIDs:
16982732 27454289 26801247 25193512 29338080 25072261 25847936

Sources:
ClearityFoundationBiomarkers JAX-CKB NCI CGI CIViC
PIPERINE BRCA1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
EMODIN BRCA1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14694444

Sources:
NCI
ADAVOSERTIB BRCA1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Phase II

Response Type predicted – sensitive

PMIDs:
27998224

Sources:
JAX-CKB
QUINALIZARIN BRCA1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ACRIFLAVINE BRCA1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TEMOZOLOMIDE BRCA1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Talazoparib + Temozolomide

Indication/Tumor Type ovarian cancer

Response Type sensitive

PMIDs:
None found

Sources:
JAX-CKB
EVEROLIMUS BRCA1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

combination therapy Olaparib + Everolimus

Indication/Tumor Type triple-receptor negative breast cancer

PMIDs:
26546619

Sources:
JAX-CKB
MITOXANTRONE BRCA1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12684687

Sources:
NCI
GEMCITABINE BRCA1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12684687 29338080

Sources:
NCI CIViC
PURPURIN BRCA1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB BRCA1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25218906

Sources:
CIViC
DEPHOSTATIN BRCA1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
IRINOTECAN BRCA1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Irinotecan + Veliparib

Indication/Tumor Type ovarian cancer

Response Type predicted – sensitive

PMIDs:
26842236

Sources:
JAX-CKB
APIGENIN BRCA1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
AURINTRICARBOXYLIC ACID BRCA1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DAUNORUBICIN HYDROCHLORIDE BRCA1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PACLITAXEL BRCA1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Carboplatin + Paclitaxel + Veliparib

Indication/Tumor Type breast cancer

Response Type predicted – sensitive

PMIDs:
12684687

Sources:
JAX-CKB NCI
DOXORUBICIN HYDROCHLORIDE BRCA1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CYCLOPHOSPHAMIDE BRCA1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Veliparib + Cyclophosphamide

Indication/Tumor Type ovarian cancer

Response Type no benefit

PMIDs:
25589624

Sources:
JAX-CKB
DOXORUBICIN BRCA1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12698198

Sources:
NCI
DIPYRIDAMOLE BRCA1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
RESVERATROL BRCA1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

Ensembl: ENSG00000012048
- Version: 101_38
Alternate Names:

BRCA1 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:

JAX-CKB: BRCA1

Version: 27-September-2017

Alternate Names:

672 CKB Entrez Id

BRCA1 CKB Gene Synonym

BRCAI CKB Gene Synonym

Gene Info:

Publications:

Kummar et al., 2015, Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer., Clin. Cancer Res.

Rodler et al., 2016, Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer., Clin. Cancer Res.

Karginova et al., 2015, Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer., Mol. Cancer Ther.

PharmGKB: BRCA1

Version: 18-August-2020

Alternate Names:

PA25411 PharmGKB ID

Gene Info:

Publications:

Metcalfe K et al., 2004, Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers., J Clin Oncol

Gronwald J et al., 2006, Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update., Int J Cancer

Pierce LJ et al., 2006, Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer., J Clin Oncol

CIViC: BRCA1

Version: 14-September-2020

Alternate Names:

672 Entrez Gene ID

6 CIViC Gene ID

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE, DRUG RESISTANCE

Publications:

Xu et al., 2017, CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours., Nat Commun

Goff, 2013, Advanced ovarian cancer: what should be the standard of care?, J Gynecol Oncol

Robson et al., 2017, Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation., N. Engl. J. Med.

CGI: BRCA1

Version: 27-September-2017

Alternate Names:

Gene Info:

Publications:

Dann et al., 2012, BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer., Gynecol. Oncol.

Alsop et al., 2012, BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group., J. Clin. Oncol.

Tutt et al., 2010, Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial., Lancet

NCI: BRCA1

Version: 14-September-2017

Alternate Names:

Gene Info:

Publications:

Tassone et al., 2003, BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells., Br. J. Cancer

Jones et al., 2005, Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer., Oncogene

Quinn et al., 2003, BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis., Cancer Res.

HingoraniCasas: ENSG00000012048
- Version: 31-May-2017
Alternate Names:

ENSG00000012048 Gene Symbol

BRCA1 Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
OncoKB: BRCA1
- Version: 23-July-2020
Alternate Names:

672 OncoKB Entrez Id

RNF53 OncoKB Gene Synonym

IRIS OncoKB Gene Synonym

Gene Info:

Publications:
HumanProteinAtlas: BRCA1
- Version: 19.3
Alternate Names:

ENSG00000012048 Ensembl Gene ID

BRCC1 Human Protein Atlas Gene Synonym

FANCS Human Protein Atlas Gene Synonym

Gene Info:

Gene Categories:

ENZYME

Publications:
Tempus: BRCA1
- Version: 11-November-2018
Alternate Names:

BRCA1 Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
MskImpact: BRCA1
- Version: May-2015
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
ClearityFoundationBiomarkers: BRCA1
- Version: 26-July-2013
Alternate Names:

Gene Info:

Publications:
DTC: BRCA1
- Version: 02-September-2020
Alternate Names:

Gene Info:

Publications:
FoundationOneGenes: BRCA1
- Version: 03-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
CarisMolecularIntelligence: BRCA1
- Version: 04-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
Oncomine: BRCA1
- Version: v3
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:

Evidence Type	Emerging
Approval Status	Clinical Study
Response Type	not applicable

combination therapy	Veliparib;Cisplatin
Drug family	PARP inhibitor;Chemotherapy
Alteration	BRCA1:.

Indication/Tumor Type	ovarian cancer
Response Type	sensitive
Approval Status	FDA approved

Indication/Tumor Type	Advanced Solid Tumor
Response Type	sensitive
Approval Status	Preclinical

Indication/Tumor Type	triple-receptor negative breast cancer
Response Type	predicted – sensitive
Approval Status	Preclinical - Cell line xenograft

Indication/Tumor Type	breast cancer
Response Type	sensitive
Approval Status	Preclinical - Cell line xenograft

Indication/Tumor Type	ovarian carcinoma
Response Type	sensitive
Approval Status	Clinical Study

Evidence Type	Actionable
Approval Status	Phase I
Response Type	sensitive

combination therapy	Carboplatin + VX-970
Indication/Tumor Type	ovarian cancer
Response Type	sensitive

combination therapy	Talazoparib + Temozolomide
Indication/Tumor Type	ovarian cancer
Response Type	sensitive

combination therapy	Irinotecan + Veliparib
Indication/Tumor Type	ovarian cancer
Response Type	predicted – sensitive

combination therapy	Carboplatin + Paclitaxel + Veliparib
Indication/Tumor Type	breast cancer
Response Type	predicted – sensitive

combination therapy	Veliparib + Cyclophosphamide
Indication/Tumor Type	ovarian cancer
Response Type	no benefit

672	OncoKB Entrez Id
RNF53	OncoKB Gene Synonym
IRIS	OncoKB Gene Synonym

ENSG00000012048	Ensembl Gene ID
BRCC1	Human Protein Atlas Gene Synonym
FANCS	Human Protein Atlas Gene Synonym

BRCA1 Gene Record

BRCA1 672 Druggable GenomeClinically ActionableDrug Resistance

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Emerging Approval Status Clinical Study Response Type not applicable

PMIDs: 27322743

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Veliparib;Cisplatin Drug family PARP inhibitor;Chemotherapy Alteration BRCA1:.

PMIDs: 25589624 26801247 26842236 25824335 29338080

Sources: ClearityFoundationBiomarkers JAX-CKB CGI CIViC

Interaction Types & Directionality: n/a

Interaction Info: Alteration BRCA1:. Drug family PARP inhibitor Indication/Tumor Type breast cancer

PMIDs: 26546619 22172724 27454287 25193512 25366685 20609467 28792849 21862407 25218906 19553641 28578601 23346317 31157963 30797618 30345884 24882434 31538027

Sources: ClearityFoundationBiomarkers JAX-CKB CGI CIViC PharmGKB OncoKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28211448

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type ovarian cancer Response Type sensitive Approval Status FDA approved

PMIDs: 23810788 27717299

Sources: ClearityFoundationBiomarkers JAX-CKB PharmGKB OncoKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type Advanced Solid Tumor Response Type sensitive Approval Status Preclinical

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Emerging

Approval Status Clinical Study

Response Type not applicable

PMIDs:
27322743

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Veliparib;Cisplatin

Drug family PARP inhibitor;Chemotherapy

Alteration BRCA1:.

PMIDs:
25589624 26801247 26842236 25824335 29338080

Sources:
ClearityFoundationBiomarkers JAX-CKB CGI CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

Alteration BRCA1:.

Drug family PARP inhibitor

Indication/Tumor Type breast cancer

PMIDs:
26546619 22172724 27454287 25193512 25366685 20609467 28792849 21862407 25218906 19553641 28578601 23346317 31157963 30797618 30345884 24882434 31538027

Sources:
ClearityFoundationBiomarkers JAX-CKB CGI CIViC PharmGKB OncoKB

Interaction Types & Directionality:

n/a

PMIDs:
28211448

Sources:
CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type ovarian cancer

Response Type sensitive

Approval Status FDA approved

PMIDs:
23810788 27717299

Sources:
ClearityFoundationBiomarkers JAX-CKB PharmGKB OncoKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Preclinical

PMIDs:
26546619 28242752 23881923

Sources:
JAX-CKB CIViC PharmGKB OncoKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type triple-receptor negative breast cancer

Response Type predicted – sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
26513298

Sources:
ClearityFoundationBiomarkers JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found